Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by amorakon Apr 04, 2007 12:28am
340 Views
Post# 12544173

RE: House Positions...

RE: House Positions...I'm not sure who you're agreeing with taurusbull. I must say that I don't pay much attention to what any given house is doing unless the activity of a single client can be isolated within that house's trading activity. Especially on a busy day, there are many clients trading out of the same house and I doubt completely whether they act in concert, other than collectively being either mostly on the buy or sell. That could reflect a house's opinion but in the end, each client makes up his or her own mind. Acting in concert and collectively are completely different things. So when I hear that Canaccord or Dundee is selling today, or whatever, I don't pay much attention to it unless it's obvious they're leading the market. FIMAT is interesting because it seems to be a single trader who is very clever in the way he sets up the bid/ask so that human instinct is triggered into buying or selling into the hands of another house lurking just ahead or behind FIMAT. And that's all the ccomment I have to offer about FIMAT publicly here.
Bullboard Posts